

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Reducing self-isolation periods, Omicron breakthrough infections, hospitalisations and vaccine protection

Peer reviewed journals

- Randomised controlled trials of:
 - A single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18+ years [here](#) and associated commentary [here](#)
 - Monoclonal antibody therapies, sotrovimab and B212-196 plus B212-198, for adults hospitalised with COVID-19 [here](#) and associated commentary [here](#)
- An observational study on GP consultation rates for sequelae after acute COVID-19 [here](#)
- Commentary on the intensifying threat of COVID-19 among First Nations People of Australia [here](#)
- An editorial on post-acute COVID-19 in primary care [here](#)
- Nature research briefings on:
 - Activity of convalescent and vaccine serum against the Omicron variant [here](#)
 - Antibody evasion manifested by the Omicron variant [here](#)
 - Omicron immune escape [here](#), [here](#) and [here](#)

Letters and correspondence

- Long COVID in children [here](#) and [here](#)
- Characteristics and outcomes of hospitalised patients in South Africa during the COVID-19 Omicron wave compared with previous waves [here](#)
- Effectiveness of the Comirnaty vaccine against Omicron variant in South Africa [here](#)
- Third Comirnaty vaccination neutralization of SARS-CoV-2 Omicron infection [here](#)
- Plasma neutralisation of the SARS-CoV-2 Omicron variant [here](#)

Pre-peer review

- Early estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada [here](#)
- Short-term projections based on early Omicron variant dynamics in England [here](#)
- Forecasting COVID-19 infection trends and hospital admissions in England due to Omicron [here](#)
- Rapid increase in Omicron infections in England during December 2021: REACT-1 study [here](#)
- The use of rapid antigen testing to reduce the impact of self-isolation periods [here](#)
- Outcomes from COVID-19 in US paediatric and adult patients before and after Omicron [here](#)

- Vaccines and cellular immunity to the SARS-CoV-2 Omicron variant [here](#)
- Recognition of Omicron Spike following COVID-19 mRNA vaccination in pregnancy [here](#)
- Increased vaccine breakthrough, decreased hospitalisation rates, and less severe disease caused by Omicron in Houston, Texas [here](#)
- Humoral immune responses against SARS-CoV-2 variants including Omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine [here](#)
- Effectiveness of COVID-19 vaccines against Omicron or Delta infection [here](#)
- T cell reactivity to the SARS-CoV-2 Omicron variant [here](#)
- Effectiveness of mRNA booster vaccines against Omicron in patients with cancer [here](#)
- Infectivity and immune escape of Omicron [here](#)
- Resistance of Omicron variant to neutralisation by vaccine-elicited and therapeutic antibodies [here](#)
- Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients [here](#)
- Severity and disease spectrum of COVID-19 in children in NSW during the Delta outbreak [here](#)
- Waning of SARS-CoV-2 booster viral-load reduction effectiveness [here](#)
- Cross-reactive immune responses in vaccine-breakthrough infection by Omicron [here](#)
- Remdesivir, Molnupiravir and Nirmatrelvir against Omicron and other variants of concern [here](#)
- T cell responses against Omicron [here](#)
- Asymptomatic carriage associated with Omicron [here](#)
- Omicron transmission in Danish households [here](#)
- Two doses of mRNA vaccine and cross-neutralizing memory B-cells against Omicron [here](#)
- Serial interval and basic reproduction number of Omicron in South Korea [here](#)
- Saliva swabs for Omicron detection [here](#)
- Three doses of Comirnaty vaccine and neutralising antibody capacity against Omicron [here](#)
- Neutralizing antibodies to Omicron after third mRNA vaccination and response to a single dose in previously infected adults [here](#) and [here](#)
- Omicron outbreak at a private gathering, infecting 21 of 33 triple-vaccinated healthcare workers [here](#)

Guidance and reports

- The World Health Organization published:
 - An updated interim statement on booster doses for COVID-19 vaccination [here](#)
 - Weekly epidemiological update on COVID-19 - 28 December 2021 [here](#)
 - Updated priority actions for enhancing readiness for Omicron (B.1.1.529) [here](#)
- The UK Health Security Agency published a technical briefing on SARS-CoV-2 variants of concern and hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01 (B.1.1.529) [here](#)

News and blogs

- Safety of reducing the self-isolation period [here](#) and [here](#)
- Single measures aren't enough [here](#)
- An urgent call for global "vaccines-plus" action [here](#)
- CDC shortens isolation period as US cases hit record high [here](#)
- Early studies give hope omicron is milder than other variants [here](#) and [here](#)

